Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939809 · ClinicalTrials.gov registry record · Phase 2
A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 16
- Study locations
NCT00939809: Completed Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma, sponsored by Gynecologic Oncology Group.
NCT00939809 is a Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 31 participants, below the 123-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (75% lower). The trial reports 16 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939809, a Phase 2 study of Recurrent Ovarian Carcinoma and Primary Peritoneal Carcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 16
- Study locations
Study Summary
This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. A6 may stop the growth of tumor cells by blocking blood flow to the tumor.
Primary Outcome
Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions. CT scan or MRI is used to follow lesion for measurable disease every other cycle for the first 6 months; every three months thereafter; and at any time
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
- BIOLOGICAL Urokinase-Derived Peptide A6
Study Locations (16)
Ohio
- Case Western Reserve University - Cleveland
- MetroHealth Medical Center - Cleveland
- Cleveland Clinic Cancer Center/Fairview Hospital - Cleveland
- Riverside Methodist Hospital - Columbus
- Hillcrest Hospital Cancer Center - Mayfield Heights
Pennsylvania
- Abington Memorial Hospital - Abington
- Magee-Womens Hospital of UPMC - Pittsburgh
Georgia
- Georgia Regents University Medical Center - Augusta
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Nebraska
- Nebraska Methodist Hospital - Omaha
New York
- Stony Brook University Medical Center - Stony Brook
Oklahoma
- University of Oklahoma Health Sciences Center - Oklahoma City
Rhode Island
- Women and Infants Hospital - Providence
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2009-07 |
| Phase | Phase 2 |
What the finished NCT00939809 record still lists
NCT00939809 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 123-participant average among 39 other Recurrent Ovarian Carcinoma trials with a reported enrollment target (75% lower).
The record links to 10 conditions, with Recurrent Ovarian Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT00939809 lists 16 locations in 11 states (Ohio, Pennsylvania, Georgia).
Frequently Asked Questions
What is clinical trial NCT00939809 about?
NCT00939809 is a clinical study titled "A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer". This phase II trial is studying the side effects and how well A6 works in treating patients with persistent or recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer. A6 may stop the growth of tumor cells by blocking blood flow to the tumor.
What is the current status of trial NCT00939809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2009-07.
What conditions does trial NCT00939809 study?
This clinical trial studies the following conditions: Recurrent Ovarian Carcinoma, Primary Peritoneal Carcinoma, Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Carcinoma, Ovarian Brenner Tumor.
What interventions are being tested in trial NCT00939809?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Urokinase-Derived Peptide A6 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00939809?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00939809 being conducted?
This trial has 16 study locations across Georgia, Iowa, Nebraska, New York, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Ovarian Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00939809's enrollment target sits among peer trials
31 28th of 39 higher than 11 of 39 other Recurrent Ovarian Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Ovarian Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer
RECRUITING · Phase 2
-
Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
RECRUITING · Phase 2
-
ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer
RECRUITING · Phase 2
-
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability
RECRUITING · Phase 2
-
Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia